Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.


TSXV:XRTX - Post by User

Comment by Richmondon Sep 30, 2021 1:47pm
146 Views
Post# 33946653

RE:RE:Analyst : XORTX Price target $27 USD

RE:RE:Analyst : XORTX Price target $27 USDWell, after the Rollback of almost 12 to 1 , early September, the SHAREPRICE was around $9++, so to get to Nasdaq with 10M shares and a market of cap $60M is very cheap. XORTEX Lost $3++ after Rollback. IPO of US $50+ would be relevant with 100M shares, if able to convince and secure good underwriters. Shareprice Would be based upon NASDAQ IPO.....after sucees and patent 3rd trial............ Lets see what Anklebiter42 comes up with. US$27 is a Target at what time frame?..... Wait and Watch.............
SpaceLabs wrote: Now I can see HOPE from my friend Anklebiter42 and I will stick to your advice bro.
You are upto date with stock information and i shall be listening to you. I went to Barrons site and looks pretty good when INDICATOR is STRONG BUY !

Thanks for this AB42, now i will make some money on my $2000 in XRX and I will buy more on its way UP !
Thx again dude, lets get listed on NASDAQ. 
Any idea about #of shrs to be IPO'd?






Anklebiter42 wrote: https://www.barrons.com/market-data/stocks/xrtxd/research-ratings




<< Previous
Bullboard Posts
Next >>